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Aspirin is considered an aﬀ ordable and widely available, 
if only modestly eﬀ ective, thromboprophylactic for 
secondary stroke prevention. The two large randomised 
controlled trials of aspirin in acute ischaemic stroke 
reported that aspirin reduced the odds of early recurrent 
stroke at 2–4 weeks by about 12% (odds ratio [OR] 0·88, 
95% CI 0·79–0·97) and the odds of death or dependency 
at the end of follow-up by about 5% (OR 0·95, 
0·91–0·99).1 The ten trials of aspirin for long-term 
secondary prevention in patients with previous transient 
ischaemic attack (TIA) or ischaemic stroke reported that 
aspirin reduced the risk of any recurrent stroke over 
3 years by about 17% (relative risk [RR] 0·83, 95% CI 
0·72–0·96).2 However, non-randomised observational 
studies have suggested that urgent medical treatments, 
including aspirin, in acute TIA and mild ischaemic stroke 
reduce the risk of recurrent stroke by up to 80%.3
In The Lancet, Peter Rothwell and colleagues4 report 
ﬁ ndings from an analysis of the individual patient data 
from all randomised controlled trials of aspirin after 
ischaemic stroke or TIA, giving fresh insights into the 
eﬀ ect of aspirin on the timing and severity of recurrent 
stroke and challenging our understanding of the role of 
aspirin in secondary stroke prevention.
Rothwell and colleagues found that in the three trials of 
aspirin versus control in acute ischaemic stroke (n=40 531), 
the overall eﬀ ect of aspirin was indeed modest. However, 
there was signiﬁ cant heterogeneity according to baseline 
stroke severity (phet=0·014). Aspirin appeared far more 
eﬀ ective in reducing the 14 day risk of recurrent ischaemic 
stroke in patients with mild (OR 0·51, 95% CI 0·34–0·75) 
and moderate (0·65, 0·44–0·98) neurological damage 
after stroke, than for those with severe deﬁ cits (OR 1·10, 
0·77–1·58). Also, the reduction in recurrent stroke among 
patients with mild and moderate stroke was as great as 
half to two-thirds within the ﬁ rst 2–6 days.
Moreover, among the 12 trials of secondary prevention 
of stroke in 15 778 patients with TIA or ischaemic 
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The HubBLe study can help establish realistic patient 
expectations and provide a framework for counselling 
patients. This study has been a trend setter in selecting 
patient-reported outcomes as the primary endpoint. In 
context, patient-reported outcomes are now widely used, 
although this development is recent.10 Use of a patient-
centric qualitative endpoint is underpinned by the high-
quality health economics model applied in HubBLe.
The role of HAL, which has become widely accepted 
as a safe intervention for grade II–III haemorrhoids, will 
need re-evaluation. However, HAL might ﬁ nd a niche 
role as second-line treatment for patients who relapse 
following a course of RBL and do not wish to have 
excisional haemorrhoidectomy.
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stroke randomised to aspirin or control, aspirin reduced 
the 12 week risk of any stroke by half (hazard ratio 
0·49, 95% CI 0·40–0·60), disabling or fatal ischaemic 
stroke by two-thirds (0·34, 0·25–0·46), and acute 
myocardial infarction by two-thirds (0·30, 0·17–0·52). 
The eﬀ ect of aspirin was consistent among the trials and 
independent of patient characteristics, stroke aetiology, 
and aspirin dose. The eﬀ ect of aspirin was however, greater 
in the ﬁ rst 6 weeks after randomisation (indeed greatest in 
the ﬁ rst 2 weeks) than the second 6 weeks, and attenuated 
further to be of limited long-term beneﬁ t thereafter.
Among seven trials of dipyridamole plus aspirin 
versus aspirin in 9437 patients, the addition of 
dipyridamole to aspirin had no eﬀ ect on the risk or 
severity of recurrent ischaemic stroke within 12 weeks, 
but did reduce risk thereafter, particularly of disabling or 
fatal ischaemic stroke.4
These results suggest that we might have under-
estimated the eﬀ ect of aspirin in preventing early 
recurrent stroke and myocardial infarction after TIA and 
ischaemic stroke, overestimated the eﬀ ect of aspirin in 
preventing long-term recurrent stroke, been unaware 
of the beneﬁ ts of aspirin in reducing the severity of early 
recurrent ischaemic stroke, and underestimated the eﬀ ect 
of dipyridamole in preventing long-term recurrent stroke. 
These results have implications for clinical practice.
First, patients with suspected TIA or ischaemic stroke 
require urgent assessment and intervention. These 
people have a high early risk and ongoing long-term 
risk of recurrent stroke and other vascular events unless 
the underlying cardiovascular cause and its potential 
consequences are appropriately treated.3 Second, aspirin 
is the ﬁ rst-line antithrombotic of choice and should be 
administered immediately. The beneﬁ ts in reducing 
the risk and severity of early recurrent stroke are greater 
than previously recognised. The potential risks associated 
with administering aspirin before brain imaging to 
exclude intracerebral haemorrhage (ICH) are likely to be 
low because this is a rare cause of transient or mild focal 
neurological symptoms, and the few randomised trials of 
antithrombotic therapy in such patients,1 or patients with 
intracerebral haemorrhage,5 have not reported adverse 
outcomes. However, a larger body of observational 
evidence suggests that antiplatelet therapy at the time 
of intracerebral haemorrhage might increase mortality.6 
Hence, caution and further research are warranted in 
this setting. Similarly, although observational studies 
suggest no detrimental eﬀ ect of prior antiplatelet use in 
patients with ischaemic stroke who subsequently require 
thrombolysis,7 further research is required.
The implications of these results for public education 
are to raise awareness of the nature of the symptoms and 
signs of TIA and stroke, the high risk of early recurrent 
stroke even if symptoms have subsided, and the need 
to seek medical attention immediately. For individuals 
with stroke-like symptoms that are transient and resolve 
within minutes to an hour or so, self-administration of 
aspirin, while awaiting medical assessment, is likely to be 
safe and of beneﬁ t in preventing a recurrent ischaemic 
event of the brain. For individuals with persistent stroke-
like symptoms that could possibly be due to intracerebral 
haemorrhage, the overall beneﬁ ts of self-administration 
of aspirin are also likely to oﬀ set the risks, but further 
evaluation of such a public policy is recommended.
Rothwell and colleagues are now reviewing the 
individual patient data from other trials of antiplatelet 
therapy and will shortly report on factors that could 
modify the eﬀ ects of antiplatelet drugs, and the long-
term beneﬁ ts, risks, and costs of continuing versus 
stopping speciﬁ c antiplatelet drugs in patient subgroups. 
Meanwhile, the quest continues to identify antiplatelet 
and anticoagulant regimens that are even more eﬀ ective 
than aspirin in preventing recurrent stroke, and their 
optimum timing and duration. Although there is no 
signiﬁ cant beneﬁ t of early ticagrelor compared with 
aspirin,8 the early short-term use of clopidogrel and aspirin 
in combination is more eﬀ ective than aspirin monotherapy 
in select populations.9 Trials of dual antiplatelet therapy 
(eg, adding clopidogrel10 or cilostazol11 to aspirin) and triple 
antiplatelet therapy (adding clopidogrel and dipyridamole 
to aspirin12) are ongoing in other populations, and trials of 
a potent selective protease-activated receptor-4 (PAR4) 
antagonist and new direct oral anticoagulants are planned. 
Future trials should measure the severity, as well as the 
incidence, cause, and timing of recurrent vascular events.
Graeme J Hankey
School of Medicine & Pharmacology, The University of Western 
Australia, Perth, WA 6009, Australia; Department of Neurology, 
Sir Charles Gairdner Hospital, Perth, WA, Australia; and
Western Australian Neuroscience Research Institute (WANRI), 
Perth, WA, Australia
graeme.hankey@uwa.edu.au
GJH has received honoraria from AC Immune for chairing the data safety 
monitoring committee of two clinical trials of vaccines for Alzheimer’s disease, 
Comment
314 www.thelancet.com   Vol 388   July 23, 2016
In The Lancet, Fiona J Charlson and colleagues1 use data 
from the Global Burden of Disease Study 2013 to show 
the substantial disease burden associated with mental, 
neurological, and substance use disorders, as well as the 
probable health service and workforce challenges that will 
continue to emerge in the coming decades for both China 
and India. According to their new analysis, the two most 
populous nations in the world, India and China, account for 
32% of the disease burden of global mental, neurological, 
and substance use disorders, which is greater than that in 
all developed countries combined. China accounts for 17% 
and India accounts for 15%, with depressive disorders and 
anxiety disorders being the most common.
The eﬀ ects of mental, neurological, and substance 
use disorders in these countries extend far beyond the 
individual. The stigma associated with mental health 
impacts on employment opportunities and thus material 
circumstances and the social economic status of the 
family, compounding social inequities for those with 
mental, neurological, and substance use disorders. These 
wider implications have not been addressed in the 
generally descriptive analysis by Charlson and colleagues,1 
which they acknowledge. Thus, the burden of mental, 
neurological, and substance use disorders described in 
China and India is very likely an underestimate of the 
true eﬀ ect of such disorders in these populations. The 
analysis also overlooks the likely large regional diﬀ erences 
in the burden of such disorders across both countries. We 
know, for example, that there is substantial geographical 
variation across non-communicable disease outcomes 
in China generally,2,3 including suicide,4 which reﬂ ects the 
heterogeneity in social, economic, demographic, cultural, 
and health service factors that are likely determinants of 
mental health outcomes. More geographically speciﬁ c 
estimates can provide a detailed understanding of local 
context, and health and social service needs in addressing 
the disease burden associated with mental, neurological, 
and substance use disorders. We also know there are 
substantial barriers to mental health care in both China 
and India—most individuals with mental illnesses do not 
access psychiatric health services.5–7
In recent years in China there has been the development 
of a series of national mental health policy reforms 
relating to the expansion of acute and community-
based mental health care.8–10 The recently implemented 
national mental health laws in China in 20129 are helping 
to develop capacity in acute and community-based care 
for severe mental disorders, regulating the diagnosis 
and treatment of mental disorders, and establishing 
health institutes and institutional capacity for health 
professionals in the diagnosis and treatment of mental 
disorders. The integration of mental health care with 
community-based services for early detection and 
treatment and rehabilitation is also prominent in these 
Reforming mental health in China and India
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